Osteoporosis, Clinical Reviews in Bone and Mineral Metabolism | DeepDive (2023)

  • New treatments for the growing plague of brittle bones

    Wilson, JF

  • The global problem of osteoporosis: insights from epidemiology

    Riggs, BL; Melton, LJ

  • Hip fractures in the elderly: a comprehensive view

    Kuiper, C; Campion, G; Melton, LJ

  • Osteoporosis - a global problem and its impact in Asia

    Lau, EM

  • Epidemiology and outcomes of osteoporotic fractures

    Cummings, SR; Melton, LJ

  • osteoporosis

    Lee, CA; Einhorn, TA

  • Bone matrix proteins: function, regulation and their relationship to osteoporosis

    Young, M.F

  • Invited review: pathogenesis van osteoporosis

    Seeman, E

  • Regulation of bone remodeling and emerging novel drugs for osteoporosis and osteolytic bone metastases

    Boyce, φίλε? Xing, L; Shakespear, W.

  • Genetic control of osteoporosis susceptibility

    Ralston, SH

  • Osteoclast differentiation and activation

    Boyle, WJ; Simonet, WS; Lacy, DL

  • Self-assessment program for pharmacotherapy

    Follin, SL

  • Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKI

    Yasuda, Η., Shima, Ν;

  • Osteoprotegerin ligand (OPGL) directly activates mature osteoclasts

    Burgess, TL; Qian, Y; Kaufman, S

  • Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

    Simonet, WS; Lacey, DL; Dunstan, CR

  • Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

    Yasuda, Η., Shima, Ν;

  • Mice deficient in osteoproteogens develop early osteoporosis and arterial calcification

    Buçay, Ν; Saros, ik; Dunstan, CR

  • Severe osteoporosis in mice lacking osteoclastogenesis inhibitor/osteoprotegrin

    Mizuno, Ah? Amizuka, N; Irie, K

  • Consensus Development Conference: Diagnosis, Prevention and Treatment of Osteoporosis

  • Cecil Manual of Medicine

    Finkelstein, JS

  • Bone strength and its determinants

    Amman, R; Rizzoli, R

  • osteoporosis

    Orwoll, ES; small, r

  • Understanding osteoporosis and its treatment

    Vogelbos, G

  • Clinical review 123: Anabolic therapy for osteoporosis

    Rosen, CJ; Bilezikian, JP

  • Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis

    Riggs, BL; Hodgson, SF; O'Fallon, WM

  • A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis

    Kleerekoper, M; Peterson, E.L.; Nelson, DA

  • Treatment of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone mineral density and fracture rate

    Ring, JD; Kipshoven, C; Koster, Ah? Ubach, R

  • Effect of raloxifene in combination with monofluorophosphate compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized controlled trial

    Join, YOU Felsenberg, D; Pav, me

  • A randomized trial of sodium fluoride (60 mg)+/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride. Estrogen coadministration prevents peripheral loss but not vertebral fractures

    Gutteridge, DH; Stewart, GAAN; Prins, R.L

  • Fluoride is no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO study

    Meunier, P.J.; Sebert, J.L.; Register, YOU

  • Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial

    Parker, CY; Sachaie, Κ; Adams-Huet, B; Piziak, V; Peterson, RD; Poindexter, JR

  • New anabolic therapies in osteoporosis

    Rubin, MR; Bilezikian, JP

  • 2002 clinical practice guidelines for the diagnosis and treatment of osteoporosis in Canada

    Brown, J.P.; Jose, R. G

  • Do statins prevent both cardiovascular disease and fractures?

    Cummings, S.R.; Bauer, DC

  • Stimulation of bone formation in vitro and in rodents by statins

    Mundy, G; Garrett, R; Harris, S

  • Direction of drug discovery in osteoporosis

    Mundy, GR

  • Effect of simvastatin treatment on bone mineral density and bone metabolism in postmenopausal women with hypercholesterolemia: a 1-year longitudinal study

    Montagnani, A; Gonnelli, S; Cepollaro, C

  • Simvastatin Increases Serum Osteocalcin Concentration in Patients Treated for Hypercholesterolemia

    Chan, ΜΗ; Mak, TW; Chiu, RW; Voer, CC; Chan, IH; Lam, CW

  • Oral statins and increased bone mineral density in postmenopausal women

    Edwards, CJ; Hart, Deejay; Spector, TD

  • Statin Use, Clinical Fractures, and BMD in Postmenopausal Women: Results from the Women's Health Initiative Observational Study

    LaCroix, AZ; Cauley, JA; Pettinger, M

  • Statin use, bone mineral density and fracture risk: the Geelong Osteoporosis Study

    Pasco, J. Α.; Kotowicz, MA; Hendrik, M.J.; Sanders, KM; Nicholson, G.C

  • Relationship between statin use and bone loss: a prospective population-based cohort study in early postmenopausal women

    Sirola, J; Honkanen, R; Kroger, H; Jurvelin, JS; Maenpaa, P; Saarikoski, S

  • Hydroxymethylglutaryl-coenzyme A reductase inhibitors and fracture risk in older women

    Chan, KA; Andrade, SE; Boles, M.

  • HMG-CoA reductase inhibitors and fracture risk

    Meier, CR; Schlienger, RG; Kranzlin, ME; Schlegel, B; Jick, H

  • HMG-CoA reductase inhibitors and risk of hip fracture in elderly patients

    Wang, PS; Solomon, DH; Mogun, H; Avorn, J

  • Statin use and fracture risk

    Staa, TP? Wegman, S; Vries, F; Leufkens, B; Kuiper, G

  • Statin use and fractures: Results of 4 prospective studies and pooled meta-analysis of observational and controlled studies

    Bauer, direct current? Mundy, G.R. Jamal, A.E

  • The effect of a single dose of osteoprotegerin in postmenopausal women

    Bekker , PJ ; Holloway , D ; I think, Α; Arrighi , M ; Leese, PT; Dunstan, CR

  • A randomized controlled trial of ONO-5920 (mindronate/YM529) in Japanese patients with postmenopausal osteoporosis

    Morii, Η Nishizawa, Υ Taketani, Υ

  • The HORIZON Recurrent Fracutre Trial: Clinical Trial Design for the Prevention of Later Fractures After Repair of Low-Trauma Hip Fractures

    Colon-Emeric, CS; Caminis , J ; Ζω, ΤΤ

  • Intravenous injections of ibandronate every three months: a new therapeutic option to prevent bone loss in postmenopausal women

    Stakkestad, JA; Benevolenskaya, LI; Stepan, JJ

  • Lupus disease activity and bone mineral density in women with active lupus: results of a double-blind, multicenter study comparing prasterone with placebo

    Petrie, M; Ramsey-Goldman, R; Manzi, S. (1999).

  • Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxbutyl ester (HCT1026)

    Panter , KJ ; Hof , RJ ; Armor, KE; Torbergsen , AC ; Στρατιώτης, P; Ralston, SH

  • Pharmacological action of a novel potent histoselective benzopyran estrogen

    Galbiati, E? Caruso, PL; Amar, G

  • The use of selective estrogen receptor modulators and selective estrogen receptor modulators in breast cancer

    Howell, SJ; Johnston, SR; Howell, A. (1999).

  • Lasofoxifene is superior to raloxifene in preventing bone loss in postmenopausal women: results after 1 year

    Bolognese, M; Mofett, A; Lee, A

  • Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-ranging studies

    Gallagher, JC; Baylink, DJ; ereburger, R; McClung, M

  • Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss

    Rymer, J; Robinson, J.; Fogelman, I

  • A randomized trial of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures

    Studd, J; Arnala, me? Kicovic, PM; Zamblera, D; Kroger, H; Holland, N

  • Changes in bone mineral density during two years of treatment with tibolone-conjugated estrogens and norgestrel compared with untreated controls in postmenopausal women

    Milner, M; Harrison, RF; Gilligan, Hu? Kelly, A

  • A synthetic peptide fragment of human MERE stimulates new bone formation in vitro and in vivo

    Hayashibara, T, Hiraga, T, Yi, B

  • Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.

    Hodsman, AB; Hanley, D.A.; Ettinger, MP

  • Apomin, a novel hypocholesterolemic agent, accelerates the breakdown of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low-density lipoprotein receptor activity

    Roitelman, J; Masson, D; Avner, R.

  • Musculoskeletal Effects of Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study

    Boonen, S; Rosen, C; Bouillon, R

  • The effects of strontium ranelate on the risk of vertebral fractures in postmenopausal women with osteoporosis

    Meunier, PJ; Roux, C; Seeman, Ε

  • AMG 162, an anti-rankl monoclonal antibody, induces a rapid, profound, and sustained reduction in bone turnover after a single dose in postmenopausal women

    Bekker, PJ; Holloway, DL; Rasmussen, AS

  • In postmenopausal women, rapid and profound suppression of bone turnover is observed over 6 months in postmenopausal women with a single subcutaneous dose of AMG 162

    Bekker, PJ; Holloway, DL; Rasmussen, AS

  • Serum concentrations of AMG 162 were maintained and bone resorption suppressed for 9 months after a single subcutaneous dose in healthy postmenopausal women

    Peterson, MC; Raak, BJ; Chen, D

  • The role of prostaglandins in the regulation of bone metabolism

    Kawaguchi, Η; Pilbeam, CC; Harrison, JR; Raisz, LG

  • Nitric oxide and bones

    Hof, RJ; Ralston, SH

  • New treatments for osteoporosis

    Biskobing, DM

  • Nitric oxide-releasing NASAIDs: an overview of their current status

    Fiorucci, S; Antonelli, Hu? Burgaud, JL; Morelli, A

  • Design of potent, selective and orally bioavailable cysteine ​​protease cathepsink inhibitors

    Tavares, FX; Boncek, V; Deton, DN

  • osteoporosis

    Wuster, C; Rosen, G

  • Association between isulin-like growth factor 1 and bone mineral density in elderly women and men: the Framingham Heart Study

    Langlois, JA; Rosen, C.J.; Vides, M

  • Low serum IGF-1 and incidence of osteoporotic fractures in postmenopausal women

    Gamero, P; Sornay-Listen, E; Delmas, P.D

  • Effects of recombinant insulin-like growth factor-I and growth hormone on bone metabolism in elderly women.

    Ghiron, LJ; Thompson, JL; Holloway, L

  • short-term effects of recombinant human insulin-like growth factor 1 on bone metabolism in normal women

    Ebeling, PR; Jones, JD; O'Fallon, WM; Janes, CH; Riggs, BL

  • Bone-specific drug delivery systems: Approaches through chemical modification of bone-seeking agents

    Hirabayashi, H Fujisaki, J

  • Will reducing bone malformation increase bone mass?: PPAR gamma2 as a key target in the treatment of age-related bone loss

    Duke, G

  • alpha(n)beta(3) Integrin antagonists as inhibitors of bone resorption

    Hartman, GD; Dugan, ME

  • Nonpeptidic alpha-3 antagonists. 8. In vitro and in vivo evaluation of a potent alpha-beta 3 antagonist for the prevention and treatment of osteoporosis

    Hutchinson, JH; Halczenko, W; Brashear, KM

  • Shik kinase activity is essential for osteoclast function

    Miyazaki, Τ; Sanjay , Α ; Neff , L ; Tanaka, S; Horn, WC; Baron, R. (1999).

  • Reduced expression of c-Src enhances osteoblast differentiation and bone formation

    Marzia, M; Sins, NA; Voit, S

  • New bone-targeting Src tyrosine kinase inhibitor drug discovery

    Shakespear, WC; Metcalf, CA; Wang, Y

  • A novel bone-targeted SRC tyrosine kinase inhibitor, AP23451, prevents bone loss in vitro and in vivo

    Boyce, man? Xing, L; Bain, S

  • Ibandronate: new options in the treatment of osteoporosis

    Adami, S; Viapiana, O

  • osteoporosis

    Stoch, SA; Chorev, M; Rosenblatt, M


How much does it cost to publish in the Journal of Bone and Mineral Metabolism? ›

To publish in Journal of Bone and Mineral Metabolism with Open Access Lincense, authors are required to pay an overall article publishing charges (APC) : $-7.0 USD.

What is Bone and mineral metabolism disease? ›

Metabolic bone diseases include osteoporosis, osteomalacia (rickets) and hyperparathyroidism. These conditions can cause weakened bone, loss of bone, frequent fractures or delayed growth in children.

What is the impact factor of Asbmr? ›

The Journal of Bone and Mineral Research (JBMR®) is the flagship peer-reviewed publication of the American Society for Bone and Mineral Research (ASBMR), and is among the highest-ranked journals in the field, with an impact factor of 6.2 (2023).

What is the impact factor of J Bone Miner Metab? ›

The 2022-2023 Journal's Impact IF of Journal of Bone and Mineral Metabolism is 2.976, which is just updated in 2023.

What are the most expensive journals to publish in? ›

Our two most expensive journals, Experimental Brain Research and Angewandte International, are commercially published, but our next most costly journals are published by the Institute of Physics, the American Institute of Physics and the Royal Society of Chemistry.

What is the ranking of Journal of Bone and Mineral Research? ›

It is published by Wiley-Blackwell. The overall rank of Journal of Bone and Mineral Research is 1715. According to SCImago Journal Rank (SJR), this journal is ranked 1.705. SCImago Journal Rank is an indicator, which measures the scientific influence of journals.

Can you get rid of metabolic bone disease? ›

Most cases of MBD can be treated. Treatment often involves splinting or casting broken bones. Calcium supplements by injection or orally (by mouth) will be necessary. In some cases antibiotics and fluids by injection may be required.

Is there a cure for metabolic bone disease? ›

A balanced diet with adequate amounts of vitamin D and calcium and an adequate amount of physical activity are needed for normal bone metabolism. Your doctor may prescribe osteoporosis medications to help slow the rate of bone loss, and in some cases, to replace the lost bone structure.

What is the most common metabolic bone disease? ›

The commonest metabolic bone diseases are osteoporosis – a generalized reduction in bone density due to an imbalance between the rates of bone formation and resorption, which can have several causes, of which oestrogen deficiency in postmenopausal women is particularly important; osteomalacia, a defect of ...

What is a good factor impact? ›

In most fields, the impact factor of 10 or greater is considered an excellent score while 3 is flagged as good and the average score is less than 1.

What does Asbmr stand for? ›

The American Society for Bone and Mineral Research - American Society for Bone and Mineral Research.

What is the impact factor of Ijedr? ›

Impact Factor : 7.37

Acceptance/Rejection Notification: Within 02-04 Days after submitting paper.

What factors affect bone metabolism? ›

Along with calcium-regulating hormones, sex hormones are also extremely important in regulating the growth of the skeleton and maintaining the mass and strength of bone. The female hormone estrogen and the male hormone testosterone both have effects on bone in men and women (Falahati-Nini, Riggs et al.

What does bone metabolism do? ›

Bone metabolism comprises the key actions. Skeletal mass, structure, and quality are accrued and maintained throughout life, and the anabolic and catabolic actions are mostly balanced due to the tight regulation of the activity of osteoblasts and osteoclasts.

What is the effect of growth hormone on bone metabolism? ›

GH directly and through IGF-I stimulates osteoblast proliferation and activity, promoting bone formation. It also stimulates osteoclast differentiation and activity, promoting bone resorption. The result is an increase in the overall rate of bone remodeling, with a net effect of bone accumulation.

How much is bone research publication fee? ›

The JBMR® charges a fee of $50.00 US for all unsolicited submissions with the exception of revised manuscripts, invited Reviews and Perspectives, and Letters to the Editor. There is no submission fee for ASBMR members; additional member benefits can be found here.

How much does JBC publication cost? ›

Article Publishing Charge

This ensures your article will be immediately and permanently free to access by everyone. The Article Publishing Charge for this journal is USD 2300 for society members* and USD 2800 for non-members, excluding taxes.

How much is the publication fee for JBC journal? ›

Publication charges

Article publishing charges (APCs) are reasonably priced at $2,000 for ASBMB members or $2,500 for nonmembers, excluding taxes.

What is the price of publishing in MDPI? ›

All articles published in Resources (ISSN 2079-9276) are published in full open access. An article processing charge (APC) of 1600 CHF (Swiss Francs) applies to papers accepted after peer review.


Top Articles
Latest Posts
Article information

Author: Domingo Moore

Last Updated: 23/08/2023

Views: 6564

Rating: 4.2 / 5 (73 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Domingo Moore

Birthday: 1997-05-20

Address: 6485 Kohler Route, Antonioton, VT 77375-0299

Phone: +3213869077934

Job: Sales Analyst

Hobby: Kayaking, Roller skating, Cabaret, Rugby, Homebrewing, Creative writing, amateur radio

Introduction: My name is Domingo Moore, I am a attractive, gorgeous, funny, jolly, spotless, nice, fantastic person who loves writing and wants to share my knowledge and understanding with you.